Academic Journal
Single-Dose Pharmacokinetics of Meropenem during Continuous Venovenous Hemofiltration
| Title: | Single-Dose Pharmacokinetics of Meropenem during Continuous Venovenous Hemofiltration |
|---|---|
| Authors: | Thalhammer, Florian, Schenk, Peter, Burgmann, Heinz, El Menyawi, Ibrahim, Hollenstein, Ursula M., Rosenkranz, Alexander R., Sunder-Plassmann, Gere, Breyer, Stefan, Ratheiser, Klaus |
| Source: | Antimicrobial Agents and Chemotherapy ; volume 42, issue 9, page 2417-2420 ; ISSN 0066-4804 1098-6596 |
| Publisher Information: | American Society for Microbiology |
| Publication Year: | 1998 |
| Description: | The pharmacokinetic properties of meropenem were investigated in nine critically ill patients treated by continuous venovenous hemofiltration (CVVH). All patients received one dose of 1 g of meropenem intravenously. High-flux polysulfone membranes were used as dialyzers. Meropenem levels were measured in plasma and ultrafiltrate by high-performance liquid chromatography. The total body clearance and elimination half-life were 143.7 ± 18.6 ml/min and 2.46 ± 0.41 h, respectively. The post- to prehemofiltration ratio of meropenem was 0.24 ± 0.06. Peak plasma drug concentrations measured 60 min postinfusion were 28.1 ± 2.7 μg/ml, and trough levels after 6 h of CVVH were 6.6 ± 1.5 μg/ml. The calculated total daily meropenem requirement in these patients with acute renal failure and undergoing CVVH was 2,482 ± 321 mg. Based on these data, we conclude that patients with severe infections who are undergoing CVVH can be treated effectively with 1 g of meropenem every 8 h. |
| Document Type: | article in journal/newspaper |
| Language: | English |
| DOI: | 10.1128/aac.42.9.2417 |
| DOI: | 10.1128/AAC.42.9.2417 |
| Availability: | https://doi.org/10.1128/aac.42.9.2417 https://journals.asm.org/doi/pdf/10.1128/AAC.42.9.2417 |
| Rights: | https://journals.asm.org/non-commercial-tdm-license |
| Accession Number: | edsbas.E15B8560 |
| Database: | BASE |
| DOI: | 10.1128/aac.42.9.2417 |
|---|